Ipca Labs - Awaits Fresh Triggers On Unichem, U.S. Foray; Yes Securities Lowers Rating To 'Reduce'

NDTV Profit’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer NDTV Profit’s subscribers an opportunity to expand their understanding of companies, sectors and the economy..Yes Securities Report.We interacted with Ipca Laboratories Ltd. to better assess the progress of Unichem cross selling opportunity and clarity on U.S. trajectory in standalone business. Low hanging fruit in the form of better margin is largely achieved as Unichem would report ~15% operating profit margin in FY25. Further improvement would require revenue traction which in turn is dependent on conducting bio-equivalent studies for large products in run up to dossier filings across new markets. While this would ultimately lead to better Goa site utilization (and margin), we understand the process would take about a years’ time. Company reiterated U.S. would see five-six launches in current year coupled with a similar number in next fiscal. We are cognizant Ipca was a market leader in its covered molecules prior to alerts and there has apparently not been much of price erosion in the intervening period. Even so, it would still be a slow ramp up and not a dash towards the erstwhile scale in US. We tweak estimates and still remain 5-6% below consensus expectation for FY26/27. Accordingly, lower rating to Reduce primarily as we await Unichem dossier progress and US clarity before turning constructive. Our revised target price stands at Rs 1,575 (earlier Rs 1,320) based on a 30 times FY27 EPS (versus 28 times FY26E earnings per share)..Click on the attachment to read the full report:.Telecom Check - Robust Industry Growth; Airtel’s Incremental Revenue Market Share At ~49% In Q2: Motilal Oswal.DISCLAIMERThis report is authored by an external party. NDTV Profit does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of NDTV Profit..Users have no license to copy, modify, or distribute the content without permission of the Original Owner.

Ipca Labs - Awaits Fresh Triggers On Unichem, U.S. Foray; Yes Securities Lowers Rating To 'Reduce'

The brokerage's revised target price stands at Rs 1,575 (earlier Rs 1,320) based on a 30 times FY27 EPS (versus 28 times FY26E earnings per share).

NDTV Profit

NDTV Profit

Follow Us

DISCOVER US FASTER

DOWNLOAD THE APP